Neue wissenschaftliche Erkenntnisse (§ 13): HIV-Infektion, Alter 6 bis < 18 Jahre
G-BA action
amendment
2022-09-15
Evidence-checked summary
The G-BA issued a amendment on 2022-09-15. The official page states that it took effect as follows: 15.09.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2022-08-08
30 parsed turns
Oral hearing: Dolutegravir (Neue wissenschaftliche Erkenntnisse (§ 13): HIV-Infektion, Alter 6 bis < 18 Jahre)
Official Wortprotokoll · 10 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A22-38
matched
Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 39 pages
G-BA decisions
2022-09-15
amendment
The G-BA issued a amendment on 2022-09-15. The official page states that it took effect as follows: 15.09.2022. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources